{
  "emaEpar": [],
  "fdaDrugLabel": [],
  "id": "Lutetium_Lu_177_Zalsenertant_Tetraxetan",
  "nciThesaurus": {
    "casRegistry": "",
    "chebiId": "",
    "chemicalFormula": "",
    "definition": "A radioconjugate consisting of the neurotensin receptor type 1 (NTR1) antagonist, IPN01087 (3BP-227), that is linked, via the chelating agent, dodecanetetraacetic acid (DOTA), to the beta-emitting radioisotope lutetium Lu 177, with potential antineoplastic activity and imaging activity during positron emission tomography/computed tomography (PET/CT). Upon administration, lutetium Lu 177 zalsenertant tetraxetan binds to NTR1 expressed on certain tumor cells. Upon binding and internalization, this radioconjugate specifically delivers a cytotoxic dose of beta radiation to NTR1-expressing cells. NTR1, a G-protein coupled receptor, is highly expressed in ductal pancreatic adenocarcinoma but not in normal pancreatic tissue.",
    "fdaUniiCode": "WH9EXQ390Z",
    "identifier": "C157630",
    "preferredName": "Lutetium Lu 177 Zalsenertant Tetraxetan",
    "semanticType": "Pharmacologic Substance",
    "subclassOf": [
      "C129819",
      "C2124"
    ],
    "synonyms": [
      "177Lu-3BP-227",
      "177Lu-DOTA-3BP-227",
      "177Lu-DOTA-IPN01087",
      "177Lu-IPN01087",
      "Lutetium Lu 177 DOTA-3BP-227",
      "Lutetium Lu 177 DOTA-IPN01087",
      "Lutetium Lu 177 Zalsenertant Tetraxetan",
      "ZALSENERTANT TETRAXETAN LUTETIUM LU-177"
    ]
  }
}